Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.82 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.82 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.82 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.82 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.82 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.82 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.82 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.82 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.82 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.82 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.82 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.82 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.82 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.82 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.82 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.73 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.68 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.68 |
| ▸ | RXRA | P19793 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL69789 | 0.97 | SMN1; SMN2 (0.78) | SMN1; SMN2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL7827144 | 0.93 | MAPT (0.80) | SMN1; SMN2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL7065645 | 0.92 | MAPT (0.79) | SMN1; SMN2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL11477107 | 0.91 | SMN1; SMN2 (0.69) | SMN1; SMN2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL27619975 | 0.91 | SMN1; SMN2 (0.69) | SMN1; SMN2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL284671 | 0.91 | SMN1; SMN2 (0.69) | SMN1; SMN2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL29129893 | 0.91 | SMN1; SMN2 (0.69) | SMN1; SMN2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL3814880 | 0.90 | MAPT (0.83) | SMN1; SMN2HDAC3HDAC4HDAC1HDAC7 | |
| Phenylbutanoic Acid SCHEMBL1716 | 0.90 | HDAC1 (1.00) | SMN1; SMN2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL9671779 | 0.90 | MAPT (0.83) | SMN1; SMN2HDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025054311-A1 | FORMULATION CONTAINING TAURURSODIOL AND SODIUM PHENYLBUTYRATE | AMYLYX PHARMACEUTICALS, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| CN-118903087-A | Functionalized long chain hydrocarbon mono-and dicarboxylic acids useful in the prevention or treatment of disease | 埃斯佩尔维塔治疗股份有限公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-118580143-A | Preparation method of 4-phenylbutyric acid and derivatives thereof | 北京大学 | 2024-09-03 | — | — | CN | disclosed |
| CN-114126593-B | Functionalized long chain hydrocarbon mono-and dicarboxylic acids useful in the prevention or treatment of disease | 埃斯佩尔维塔治疗股份有限公司 | 2024-07-26 | — | — | CN | disclosed |
| CN-118119386-A | Functionalized carboxylic acids and their use for treating diseases | 埃斯佩尔维塔治疗股份有限公司 | 2024-05-31 | — | — | CN | disclosed |
| US-11220475-B2 | Monomers from biomass | NDSU RESEARCH FOUNDATION (US) | 2022-01-11 | — | — | US | disclosed |
| US-20210198175-A9 | NOVEL MONOMERS FROM BIOMASS | NDSU RESEARCH FOUNDATION (US) | 2021-07-01 | — | — | US | disclosed |
| US-20200140368-A1 | NOVEL MONOMERS FROM BIOMASS | NDSU RESEARCH FOUNDATION (US) | 2020-05-07 | — | — | US | disclosed |
| US-20180093939-A9 | NOVEL MONOMERS FROM BIOMASS | NDSU RESEARCH FOUNDATION (US) | 2018-04-05 | — | — | US | disclosed |
| US-20180093939-A9 | NOVEL MONOMERS FROM BIOMASS | NDSU RESEARCH FOUNDATION (US) | 2018-04-05 | — | — | US | disclosed |
| WO-2002067654-A3 | 6-SUBSTITUTED PYRAZOLO[3,4-D]PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2002-10-31 | — | — | WO | disclosed |
| WO-2002067654-A2 | 6-SUBSTITUTED PYRAZOLO[3,4-D]PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-09-06 | — | — | WO | disclosed |
| US-20020013328-A1 | 6-Substituted pyrazolo[3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-01-31 | — | — | US | disclosed |
| EP-1121363-A2 | 6-SUBSTITUTED PYRAZOLO 3,4-d]PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2001-08-08 | — | — | EP | disclosed |
| EP-0758013-B1 | Liquid crystalline optical film, compensating film for liquid crystal display and liquid crystal display | NIPPON OIL CO LTD (JP) | 2000-10-11 | — | — | EP | disclosed |
| WO-2000021926-A2 | 6-SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-04-20 | — | — | WO | disclosed |
| US-5855971-A | Liquid crystalline optical film, compensating film for liquid crystal display comprising the liquid crystalline optical film, and liquid crystal display having the compensating film | NIPPON OIL COMPANY, LIMITED (JP) | 1999-01-05 | — | — | US | disclosed |
| EP-0758013-A1 | Liquid crystalline optical film, compensating film for liquid crystal display and liquid crystal display | NIPPON OIL COMPANY, LIMITED (JP) | 1997-02-12 | — | — | EP | disclosed |
| US-5387672-A | For use in oxygen-transporting fluids | THE UNIVERSITY OF MARYLAND AT BALTIMORE (US) | 1995-02-07 | — | — | US | disclosed |
| US-4141911-A | REACTING DICARBOXYLIC ACID WITH MONOBASIC CHROMIC SALT, SURFACTANTS | TOKYO SHIBAURA ELECTRIC CO., LTD. (JP) | 1979-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198175-A9 | NOVEL MONOMERS FROM BIOMASS | DCXR, MANBA, PGLS | SMN1; SMN2 4787/4885HDAC3 2171/4885HDAC4 2409/4885 |
| US-20180093939-A9 | NOVEL MONOMERS FROM BIOMASS | DCXR, MANBA, PGLS | SMN1; SMN2 4787/4885HDAC3 2171/4885HDAC4 2409/4885 |
| US-20020013328-A1 | 6-Substituted pyrazolo[3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors | CCNK, CCNI, CDK1 | SMN1; SMN2 3617/4885HDAC3 1499/4885HDAC4 597/4885 |
| US-20200140368-A1 | NOVEL MONOMERS FROM BIOMASS | DCXR, MANBA, PGLS | SMN1; SMN2 4787/4885HDAC3 2171/4885HDAC4 2409/4885 |
| US-11220475-B2 | Monomers from biomass | DCXR, MGAM, ALG1 | SMN1; SMN2 4608/4885HDAC3 1601/4885HDAC4 2114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.